Business
Factor Bioscience Files Complaint Against Cellectis and AstraZeneca Alleging Infringement of Foundational Gene-Editing Patents
Factor Bioscience Inc. (Factor), a Cambridge, Massachusetts-based biotechnology company focused on using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced a complaint filed against Cellectis Inc., Cellectis SA, AstraZeneca PLC, AstraZeneca Ireland Limited, and AstraZeneca Holdings B.V.
About this update from Cellectis S.a.
[{"type":"list","items":[{"val":[{"type":"text","content":"Alleges infringement of three U.S. gene-editing patents","length":55,"tagName":"p"}]},{"val":[{"type":"text","content":"Infringed patents support multiple product pipelines, including Factor's allogeneic cancer cell therapy programs","length":116,"tagName":"p"}]},{"val":[{"type":"text","content":"Cites need to take action to protect Factor's ability to bring innovative cancer treatments to patients","length":107,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":278,"olType":false},{"type":"text","content":"CAMBRIDGE, Mass., Sept. 26, 2025 /PRNewswire/ -- Factor Bioscience Inc. (Factor), a Cambridge, Massachusetts-based biotechnology company focused on using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced a complaint filed against Cellectis Inc., Cellectis SA, AstraZeneca PLC, AstraZeneca Ireland Limited, and AstraZeneca Holdings B.V.","length":391,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/Factor Bioscience)","displaySize":"","headline":null,"caption":"(PRNewsfoto/Factor Bioscience)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":102,"url":"https://media.zenfs.com/en/prnewswire.com/f6724fabd87cf8d9981e6d5930815c49"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/zHjO0jHmwqYTXIzsgm5StQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTE4MDtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/f6724fabd87cf8d9981e6d5930815c49","width":400,"height":102}},"href":"https://mma.prnewswire.com/media/1172774/FactorBioscience_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"In the complaint, Factor alleges that Cellectis transformed its research program after learning about Factor's patented mRNA TALENs technology in 2013 and proceeded to illegally exploit that technology, including in its partnership with AstraZeneca, by infringing Factor's patents.","length":289,"tagName":"p"},{"type":"text","content":""We are taking this action to protect our ability to innovate in this incredibly important area of drug development," said Dr. Matt Angel, Co-Founder, Chairman and CEO of Factor. "This is a David v. Goliath story, with our mRNA TALENs slingshot holding the key to the next generation of revolutionary cancer treatments. If large multinational pharmaceu...